Results 241 to 250 of about 195,645 (350)

The Role of Microvascular Injury in the Evolution of Idiopathic Pulmonary Fibrosis [PDF]

, 2003
Patrick P. Moh, Patrick Ross, Patrick Ross, Patrick Ross, Amy Pope‐Harman, Patrick Ross, Patrick P. Moh, Susan Rothrauff, Patrick Ross, W. James Waldman, Patrick Ross, Cynthia M. Magro, James N. Allen, Susan Rothrauff   +13 more
openalex   +1 more source

Development and Validation of a Clinical Scoring System Predicting 30‐Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Respirology, EarlyView.
A scoring system using eight clinical variables was developed and validated to predict 30‐day mortality in acute exacerbation of idiopathic pulmonary fibrosis. The model showed good performance in both derivation and validation cohorts, providing a practical bedside tool for early risk stratification.
Joong‐Yub Kim, Jayoun Kim, Myeong Geun Choi, Min Jee Kim, Yun Hae Ahn, Nakwon Kwak, Jaeyoung Cho, Jinwoo Lee, Young Sik Park, Chang‐Hoon Lee, Sang‐Min Lee, Chul‐Gyu Yoo, Jin Woo Song, Sun Mi Choi   +13 more
wiley   +1 more source

Cough in idiopathic pulmonary fibrosis: what is new. [PDF]

Breathe (Sheff)
Carvalho da Silva MA, Mouro de Santos Rolo RM, Pereira Catarata MJ, de Sousa Antunes Dias Padrão EF.   +3 more
europepmc   +1 more source

Does interferon- improve pulmonary function in idiopathic pulmonary fibrosis? [PDF]

, 2003
Antje Prasse, KM Müller, Christian Kurz, Henning Hamm, J. Christian Virchow   +4 more
openalex   +1 more source

Risk Model for Predicting Survival Outcomes Using Functional Exercise and Patient‐Reported Outcomes in Fibrotic Interstitial Lung Disease: A Prospective Observational Study

Respirology, EarlyView.
This prospective cohort study of 246 F‐ILD patients assessed disease impact using PROMs (SGRQ, SF‐36) and functional measures (1MSTS and 6MWD). Tree‐based learning identified mortality predictors, outperforming the GAP score. Patients with SGRQ > 34.5 and 1MSTS < 21 had a significantly higher mortality risk (HR = 5.13).
Lan‐Yan Yang, Hsin‐Ting Yang, Yi‐Hsuan Yu, Pin‐Kuei Fu   +3 more
wiley   +1 more source

Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis. [PDF]

Eur Respir J
Selman M, Buendia-Roldan I, Pardo A.
europepmc   +1 more source

The Therapeutic Effect of Angiotensin II Receptor Antagonist in Idiopathic Pulmonary Fibrosis [PDF]

, 2003
Duck Soo Woo, Won Jong Seol, Sun Young Kyung, Young Hee Lim, Chang Hyeok An, Jeong Woong Park, Sung Hwan Jeong, Jae Woong Lee   +7 more
openalex   +1 more source

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.

Pharmacology and Therapeutics, 2020
P. Spagnolo, J. Kropski, Mark G. Jones, Joyce S. Lee, G. Rossi, T. Karampitsakos, T. Maher, A. Tzouvelekis, C. Ryerson   +8 more
semanticscholar   +1 more source

Analysis of Late Complications Associated With Hematopoietic Stem Cell Transplantation in Patients With Dyskeratosis Congenita

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Background Dyskeratosis congenita (DKC) is a genetic disorder frequently complicated by bone marrow failure (BMF). Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for BMF in DKC. However, late complications of DKC, especially pulmonary fibrosis (PF), pose significant challenges.
Takashi Koike, Shohei Yamamoto, Mayuko Shibata, Kohei Otsuka, Yumiko Sugishita, Ryota Kaneko, Naoko Kawabata, Sachio Fujita, Kosuke Akiyama, Daisuke Toyama, Miharu Yabe, Atsushi Uchiyama, Hiromasa Yabe   +12 more
wiley   +1 more source

Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis. [PDF]

Int J Mol Sci
Jones N, Rahar B, Bernau K, Schulte JJ, Campagnola PJ, Brasier AR.   +5 more
europepmc   +1 more source